Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)

Q: What does CUSIP 004890109 represent in this 13F holders report?

CUSIP 004890109 is the security identifier for ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q1 2024?

45 institutional investors reported ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q1 2024. Use the holders table for investor-level position and value details.

CUSIP: 004890109

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 42,655,924
Total 13F shares: 15,245,438
Share change: +378,770
Total reported value: $109,005,559
Price per share: $7.15
Number of holders: 45
Value change: +$3,386,877
Number of buys: 22
Number of sells: 13

Quarterly Holders Quick Answers

What is CUSIP 004890109?
CUSIP 004890109 identifies ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2024
Previous quarter: Q4 2023

Recent filing periods for CUSIP 004890109:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
RA CAPITAL MANAGEMENT, L.P.	13F	Company	11%	4,810,508	$23,667,699	—	31 Dec 2023	13F
Chione Ltd	3/4/5	10%+ Owner	— class O/S missing	3,848,632	$16,741,549	—	26 Jun 2023	3/4/5
PERCEPTIVE ADVISORS LLC	13F	Company	7.1%	3,007,858	$14,798,661	—	31 Dec 2023	13F
Sands Capital Alternatives, LLC	13F	Company	3.9%	1,652,605	$8,130,817	—	31 Dec 2023	13F
CITADEL ADVISORS LLC	13F	Company	3.9%	1,649,659	$8,116,322	—	31 Dec 2023	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	2.1%	888,130	$4,369,600	—	31 Dec 2023	13F
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.	3/4/5	10%+ Owner	— class O/S missing	888,130	$3,863,366	—	17 Nov 2022	3/4/5
MARSHALL WACE, LLP	13F	Company	1.4%	597,469	$2,939,548	—	31 Dec 2023	13F
BlackRock Finance, Inc.	13F	Company	1.3%	565,832	$2,783,893	—	31 Dec 2023	13F
VANGUARD GROUP INC	13F	Company	1.1%	475,977	$2,341,807	—	31 Dec 2023	13F
NEA Management Company, LLC	13F	Company	1%	430,252	$1,287,333	—	31 Dec 2023	13F
FEDERATED HERMES, INC.	13F	Company	0.53%	226,375	$1,113,765	—	31 Dec 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.44%	189,200	$930,982	—	31 Dec 2023	13F
STATE STREET CORP	13F	Company	0.31%	133,276	$655,718	—	31 Dec 2023	13F
DAFNA Capital Management LLC	13F	Company	0.31%	131,351	$646,247	—	31 Dec 2023	13F
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	13F	Company	0.22%	93,443	$459,740	—	31 Dec 2023	13F
NORTHERN TRUST CORP	13F	Company	0.19%	80,149	$394,333	—	31 Dec 2023	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.16%	68,501	$337,025	—	31 Dec 2023	13F
JACOBS LEVY EQUITY MANAGEMENT, INC	13F	Company	0.11%	46,072	$226,674	—	31 Dec 2023	13F
JPMORGAN CHASE & CO	13F	Company	0.08%	33,343	$164,047	—	31 Dec 2023	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.07%	31,981	$157,347	—	31 Dec 2023	13F
D. E. Shaw & Co., Inc.	13F	Company	0.07%	31,939	$157,140	—	31 Dec 2023	13F
MORGAN STANLEY	13F	Company	0.06%	25,631	$126,105	—	31 Dec 2023	13F
Bank of New York Mellon Corp	13F	Company	0.06%	24,795	$121,991	—	31 Dec 2023	13F
BARCLAYS PLC	13F	Company	0.06%	24,484	$120,461	—	31 Dec 2023	13F
EXCHANGE TRADED CONCEPTS, LLC	13F	Company	0.03%	13,289	$65,382	—	31 Dec 2023	13F
Marex Group plc	13F	Company	0.03%	13,187	$64,880	—	31 Dec 2023	13F
Nuveen Asset Management, LLC	13F	Company	0.03%	11,821	$58,159	—	31 Dec 2023	13F
AAF Wealth Management, LLC	13F	Company	0.03%	10,678	$52,536	—	31 Dec 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.02%	10,088	$49,633	—	31 Dec 2023	13F
RHUMBLINE ADVISERS	13F	Company	0.02%	9,270	$45,603	—	31 Dec 2023	13F
AMERICAN INTERNATIONAL GROUP, INC.	13F	Company	0.01%	4,321	$21,259	—	31 Dec 2023	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.01%	2,691	$13,240	—	31 Dec 2023	13F
ROYAL BANK OF CANADA	13F	Company	0.01%	2,488	$12,000	—	31 Dec 2023	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.01%	2,273	$11,183	—	31 Dec 2023	13F
CITIGROUP INC	13F	Company	0%	2,047	$10,071	—	31 Dec 2023	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	2,018	$9,929	—	31 Dec 2023	13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	13F	Company	0%	1,431	$7,041	—	31 Dec 2023	13F
AMALGAMATED BANK	13F	Company	0%	1,231	$6,000	—	31 Dec 2023	13F
Legal & General Group Plc	13F	Company	0%	839	$4,128	—	31 Dec 2023	13F
FMR LLC	13F	Company	0%	806	$3,966	—	31 Dec 2023	13F
Ameritas Investment Partners, Inc.	13F	Company	0%	695	$3,419	—	31 Dec 2023	13F
STRS OHIO	13F	Company	0%	800	$3,000	—	31 Dec 2023	13F
Qube Research & Technologies Ltd	13F	Company	0%	260	$1,279	—	31 Dec 2023	13F

Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) as of Q1 2024

As of 31 Mar 2024, Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) was held by 45 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 15,245,438 shares. The largest 10 holders included RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, CITADEL ADVISORS LLC, Sands Capital Ventures, LLC, WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., MARSHALL WACE, LLP, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, and STATE STREET CORP. This page lists 45 institutional shareholders reporting positions in this security for the Q1 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2024 vs Q4 2023 Across Filers

Q4 2023 holders

Q1 2024 holders

Holder diff

Investor	Q4 2023 Shares	Q1 2024 Shares	Share Diff	Share Chg %	Q4 2023 Value $	Q1 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.